Latest research on Lucentis

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name Lucentis®. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.

Lucentis indications

We report a systematic comparison of the three costing approaches in IVAN: a non-inferiority randomised controlled factorial trial of treatment regimens for age-related macular degeneration (AMD), where policy makers are interested in the efficacy and cost-effectiveness of two dosing regimens of bevacizumab (Avastin) and ranibizumab (Lucentis). [source, 2011]
The six-month data from two phase III Genentech-sponsored studies (BRAVO studying the effects of BRVO and CRUISE studying the effects of CRVO) evaluating the safety and efficacy of Lucentis, compared to sham, for the treatment of macular edema in RVO, were presented at the Retina Congress 2009.58,59 BRAVO reported a 7.6 and 7.4 mean letter gain in the 0.3 mg and 0.5 mg study arms of Lucentis respectively, compared to 1.9 letters gained in the sham injection arm. [source, 2010]
A recent analysis of safety in diabetic and nondiabetic patients with AMD from the AMD trials Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR), Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA), Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovasularization with or without Classic CNV Secondary to Age-Related Macular Degeneration (PIER), the Safety Assessment of Intravitreal Lucentis for AMD (SAILOR), EXCITE, and EXTEND I (N = 3,736) has revealed that the incidences of endophthalmitis were comparable between the diabetic (0.4% [2 of 523]) and nondiabetic patients (0.5% [17 of 3,213]) with AMD, with no indication of increased risk for the diabetic population (24). [source, 2010]
The purpose of this study is to compare the safety and effectiveness of three doses of intra-vitreal bevasiranib sodium as maintenance therapy for AMD following initiation of anti-VEGF therapy with three doses of Lucentis.44 [source, 2010]
Subsequently, it was shown that Lucentis was more effective than Macugen and could prevent further vision loss: about 95% of patients maintained their baseline vision whilst on treatment. [source, 2008]